BACKGROUND: New HIV infections are being observed among men who have sex with men (MSM). Understanding the fusion of risky sexual behaviors, stimulant and erectile dysfunction drug use with HIV seroconversion may provide direction for focused intervention. METHODS: During the follow-up period (1998-2008), we identified 57 HIV seroconverters among 1667 initially HIV-seronegative men. Time to seroconversion was modeled using Cox proportional hazards regression analysis for 7 combinations of sex drugs (inhaled nitrites or "poppers", stimulants, and erectile dysfunction drugs) used at the current or previous semiannual visit, adjusting for other risk factors including sexual behavior, alcohol and other drugs used, and depression. Model-based adjusted attributable risks were then calculated. RESULTS: The risk of seroconversion increased linearly with the number of unprotected receptive anal sex partners (URASP), with hazard ratios ranging from 1.73 [95% confidence interval (CI): 0.75 to 4.01] for 1 partner, to 4.23 (95% CI: 1.76 to 10.17) for 2-4 partners, and to 14.21 (95% CI: 6.27 to 32.20) for 5+ partners, independent of other risk factors. After adjustment, risks for seroconversion increased from 2.99 (95% CI: 1.02 to 8.76) for men who reported using stimulants only (1 drug) to 8.45 (95% CI: 2.67 to 26.71) for men who reported using all 3 sex drugs. The use of any of the 7 possible sex drug combinations accounted for 63% of the 9-year HIV seroincidence in the Multicenter AIDS Cohort Study. When contributions of increased URASP and combination drug use were analyzed together, the total attributable risk for HIV seroconversion was 74%, with 41% attributable to URASP alone and a residual of 33% due to other direct or indirect effects of sex drug use. CONCLUSIONS: Use of poppers, stimulants, and erectile dysfunction drugs increased risk for HIV seroconversion significantly in this cohort. These data reinforce the importance of implementing interventions that target drug reduction as part of comprehensive and efficacious HIV prevention strategies.
BACKGROUND: New HIV infections are being observed among men who have sex with men (MSM). Understanding the fusion of risky sexual behaviors, stimulant and erectile dysfunction drug use with HIV seroconversion may provide direction for focused intervention. METHODS: During the follow-up period (1998-2008), we identified 57 HIV seroconverters among 1667 initially HIV-seronegative men. Time to seroconversion was modeled using Cox proportional hazards regression analysis for 7 combinations of sex drugs (inhaled nitrites or "poppers", stimulants, and erectile dysfunction drugs) used at the current or previous semiannual visit, adjusting for other risk factors including sexual behavior, alcohol and other drugs used, and depression. Model-based adjusted attributable risks were then calculated. RESULTS: The risk of seroconversion increased linearly with the number of unprotected receptive anal sex partners (URASP), with hazard ratios ranging from 1.73 [95% confidence interval (CI): 0.75 to 4.01] for 1 partner, to 4.23 (95% CI: 1.76 to 10.17) for 2-4 partners, and to 14.21 (95% CI: 6.27 to 32.20) for 5+ partners, independent of other risk factors. After adjustment, risks for seroconversion increased from 2.99 (95% CI: 1.02 to 8.76) for men who reported using stimulants only (1 drug) to 8.45 (95% CI: 2.67 to 26.71) for men who reported using all 3 sex drugs. The use of any of the 7 possible sex drug combinations accounted for 63% of the 9-year HIV seroincidence in the Multicenter AIDS Cohort Study. When contributions of increased URASP and combination drug use were analyzed together, the total attributable risk for HIV seroconversion was 74%, with 41% attributable to URASP alone and a residual of 33% due to other direct or indirect effects of sex drug use. CONCLUSIONS: Use of poppers, stimulants, and erectile dysfunction drugs increased risk for HIV seroconversion significantly in this cohort. These data reinforce the importance of implementing interventions that target drug reduction as part of comprehensive and efficacious HIV prevention strategies.
Authors: Michael W Plankey; David G Ostrow; Ron Stall; Christopher Cox; Xiuhong Li; James A Peck; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Kate Buchacz; Willi McFarland; Timothy A Kellogg; Lisa Loeb; Scott D Holmberg; James Dilley; Jeffrey D Klausner Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Matthew J Mimiaga; Nicolas Suarez; Robert Garofalo; John Frank; Adedotun Ogunbajo; Emily Brown; Anna Bratcher; Dana Pardee; Marco A Hidalgo; Sam Hoehnle; Arjee Restar; Taylor Wimbly; Jennie Thai; Patrick S Sullivan; Rob Stephenson Journal: Arch Sex Behav Date: 2019-02-26
Authors: Philip A Chan; Jennifer Rose; Justine Maher; Stacey Benben; Kristen Pfeiffer; Alexi Almonte; Joanna Poceta; Catherine E Oldenburg; Sharon Parker; Brandon Dl Marshall; Mickey Lally; Kenneth Mayer; Leandro Mena; Rupa Patel; Amy S Nunn Journal: AIDS Patient Care STDS Date: 2015-09-21 Impact factor: 5.078
Authors: Heather L Armstrong; Eric Abella Roth; Ashleigh Rich; Nathan J Lachowsky; Zishan Cui; Paul Sereda; Kiffer G Card; Jody Jollimore; Terry Howard; David M Moore; Robert S Hogg Journal: AIDS Care Date: 2018-03-20
Authors: Leslie L Wright; Leah E Squires; Tracie M Goodness; Stephen A Maisto; Tibor P Palfai Journal: Addict Behav Date: 2013-03-14 Impact factor: 3.913
Authors: Raphael J Landovitz; Matthew Beymer; Ryan Kofron; Kathy Rivet Amico; Christina Psaros; Lane Bushman; Peter L Anderson; Risa Flynn; David P Lee; Robert K Bolan; Wilbert C Jordan; Chi-Hong Tseng; Rhodri Dierst-Davies; Jim Rooney; Amy Rock Wohl Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731